OTLK Stock Surges After FDA Ends Decade-Long Wait For Ophthalmic Bevacizumab
Shares of Outlook Therapeutics (OTLK) climbed about 6% on Friday after the company announced that the U.S. Food and Drug Administration approved its flagship eye treatment after multiple setbacks.The biotech firm’s stock closed higher following news that its LYTENAVA became the first and only FDA-a…